Adocia Publishes its Letter to Shareholders

Rhea-AI Summary

Adocia, a clinical-stage biopharmaceutical company based in Lyon, France, has released its Letter to Shareholders for the first semester of 2022. Focused on innovative solutions for diabetes and metabolic diseases, Adocia is advancing through its proprietary technologies, including BioChaperone, AdOral, and AdoShell Islets, and holds over 25 patent families. The next financial update is scheduled for August 24, 2022. Investors should note the potential risks associated with the company's forward-looking statements, including uncertainties related to research and development.

Positive

• Adocia specializes in the development of innovative therapies for diabetes and metabolic diseases.
• Holds over 25 patent families, indicating a strong intellectual property portfolio.
• Utilizes proprietary technologies like BioChaperone and AdOral, which could enhance competitive positioning.

Negative

• Forward-looking statements are subject to numerous risks, including uncertainties in research and development.

LYON, France--(BUSINESS WIRE)-- Regulatory News:

Adocia (Euronext Paris : FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the publication of the Letter to Shareholders for the 1st semester of 2022.

Read the Letter to Shareholders by clicking here

Next publication: 2nd quarter sales, 24 August 2022

About Adocia

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The company has a broad portfolio of drug candidates based on three proprietary technology platforms:

1) The BioChaperone^® technology for the development of new generation insulins and products combining insulins with other classes of hormones; 2) AdOral^®, an oral peptide delivery technology; 3) AdoShell^® Islets, an immunoprotective biomaterial for cell transplantation with a first application in pancreatic cells transplantation for patients with "brittle" diabetes.

Adocia holds more than 25 patent families.

Based in Lyon, the company has 115 employees. Adocia is listed on the Euronext^TM Paris market (Euronext: ADOC; ISIN: FR0011184241).

Disclaimer

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those which are set forth in the “Risk Factors” section of the universal registration document that was filed with the French Autorité des marchés financiers on April 21, 2022 (a copy of which is available at www.adocia.com), in particular uncertainties that are linked to research and development, future clinical data, analyses, and the evolution of the economic context, the financial markets and the markets in which Adocia operates.
The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia as of this day. The occurrence of all or part of such risks could cause that actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.
This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia’s shares in any jurisdiction.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005792/en/

Adocia

Gérard Soula

CEO

contactinvestisseurs@adocia.com

Tel : +33 4 72 610 610

www.adocia.com

Adocia Press and Investors Relations

Ulysse Communication

Pierre-Louis Germain

Margaux Puech Pays d’Alissac

Bruno Arabian

adocia@ulysse-communication.com

+33 (0)6 64 79 97 51

Source: Adocia

FAQ

What is the focus of Adocia as announced in the press release?

Adocia focuses on innovative therapeutic solutions for diabetes and other metabolic diseases.

When is Adocia's next financial update scheduled?

Adocia's next financial update is scheduled for August 24, 2022.

How many patent families does Adocia hold?

Adocia holds over 25 patent families.

What proprietary technologies does Adocia utilize?

Adocia utilizes BioChaperone, AdOral, and AdoShell Islets technologies.

What are the risks associated with Adocia's forward-looking statements?

Risks include uncertainties related to research and development, clinical data, and market conditions.